Work

Tratamento das micobacterioses não tuberculosas: revisão integrativa da literatura (2020–2026)

Year: 2026
Type: article
Study design: Systematic Review
Abstract: This integrative review examines recent evidence on the treatment of nontuberculous mycobacterial pulmonary disease, a condition characterized by prolonged treatment, significant toxicity, and modest outcomes. The study aimed to synthesize findings published between 2020 and 2026 regarding therapeutic regimens, tolerability, treatment adherence, clinical outcomes, and emerging therapies. The literature search was conducted in PubMed/MEDLINE, supplemented by manual searches and official documents, with study selection based on the PRISMA 2020 guidelines. Of the 144 records identified, 43 studies met the eligibility criteria, including clinical guidelines, clinical trials, meta-analyses, systematic reviews, and cohort studies. The combination of a macrolide, ethambutol, and a rifamycin remains the cornerstone of treatment for Mycobacterium avium complex disease, achieving treatment success in approximately two-thirds of patients. Intermittent regimens, two-drug regimens, and lower doses of ethambutol reduced toxicity while maintaining comparable efficacy in patients with the nodular-bronchiectatic form of the disease. Inhaled liposomal amikacin increased sustained culture conversion rates from 47.6% to 76.2% in newly diagnosed patients, whereas oral omadacycline demonstrated preliminary benefits against Mycobacterium abscessus. Adverse events occurred in 59% of treated patients and led to drug discontinuation in 15%, while early treatment interruption was associated with increased mortality. Completion of treatment in accordance with clinical guidelines was associated with a higher likelihood of cure and lower mortality. Evidence from Brazil remains scarce and is limited to hospital-based case series. In conclusion, treatment for nontuberculous mycobacterial pulmonary disease is advancing through the use of inhaled and repurposed drugs; however, successful management depends on species identification, drug susceptibility testing, and adherence support. These aspects need to be strengthened within the Brazilian Unified Health System (SUS), particularly in the Northern Region.
Language: English
Subfield: Epidemiology
Field: Medicine
Open Access status: hybrid
OpenAlex ID: W7236609157
FWCI:
Cites: 44
Cited by:
Related to: 10